Bo King

-Served as Clinical Development Lead and Primary Medical Monitor across oncology and rare disease programs, including DCC-3009 (pan-KIT), DCC-3084 (pan-RAF), Inlexisertib (DCC-3116), and supported Sapablursen. -Led first-in-human and early clinical development activities, including dose-escalation strategy, DLT review, safety signal assessment, dose optimization, and RP2D selection. -Served as Medical Lead for healthy volunteer, food-effect, and clinical pharmacology studies, providing medical oversight, safety review, and clinical decision-making. -Integrated safety, efficacy, PK/PD, ctDNA, and biomarker data to inform benefit-risk assessments, patient selection strategies, and clinical development decisions. -Contributed to clinical development strategy, protocol design, TPPs, regulatory submissions, and FDA interactions. -Drove global investigator engagement and development discussions across ASCO, ESMO, CTOS, ASH, and investigator meetings. -Established cross-functional clinical review forums to support risk identification, portfolio decisions, and development strategy alignment. -Led 2 of 3 first-in-human oncology programs from dose escalation through RP2D selection and supported Phase II–III development planning

Contributed to Phase 1b/2 and randomized Phase 2 oncology trials, supporting clinical development planning and execution Co-authored clinical protocols, amendments, and regulatory documents, including IND submissions Performed medical monitoring, including SAE/SUSAR assessment in collaboration with safety and regulatory teams Led clinical data review and interpretation (RECIST 1.1) to support decision-making Presented clinical data and study design at investigator meetings, advisory boards, and internal governance forums Collaborated cross-functionally with CMO, Clinical Development leadership, and external experts.

Key Projects & Contributions Led translational research strategy for multiple oncology programs, supporting progression from discovery through IND and early clinical development. Led translational research and biomarker development for AL amyloidosis, contributing to the European approval of daratumumab combination therapy. Advanced JNJ-5322, a trispecific T-cell engager targeting BCMA, GPRC5D, and CD3 for multiple myeloma. Supported development of JNJ-87189401, a costimulatory bispecific antibody targeting PSMA and CD28 for solid tumors.

Led a genome-wide CRISPR-Cas9 pooled multi-omics program to identify early diagnostic biomarkers and mechanisms of therapeutic resistance in squamous cell lung carcinoma.

Conducted pioneering research in melanoma biology and cancer immunology, uncovering novel mechanisms by which inflammatory signaling regulates tumor progression, metastasis, immune evasion, and anti-tumor immunity. Key discoveries included tumor-promoting functions of melanoma-specific IFN-γ signaling, γδ T cell–mediated modulation of the tumor microenvironment, noncanonical regulation of melanogenesis, and EGR4-dependent control of T-cell differentiation and anti-cancer immune responses.

• HLA alloantibody screening for post-transplantation patients to evaluate and monitor the outcome. • Management of patient’s database, analyzing and monitoring transplantation outcomes from patients' samples.

Working in a clinical lab setting, drafting protocol, help identify inclusion and exclusion criteria, patient selection, obtaining informed consent, data and sample collection • As a clinical scientist, performed the isolation of PBMS and monocytes • Work efficiently and precisely on the evaluation of COPD disease-related novel biomarkers by multi-colored flow cytometry • Data analysis, data interpretation, manuscript drafting, and presentations at international conferences

Physician

Major: Clinical medicine Duration : 5 years. The first 3 years was intensive in-class medicine basis learning, the last 2 years I was trained at 2 hospitals for internship.